ProCE Banner Activity

PARP Inhibitor Combination Therapies: A New Horizon in Prostate Cancer Care

Slideset Download
Download these slides from a live symposium for the latest evidence on PARP inhibitor plus AR-targeting combination therapies for the treatment of metastatic castration-resistant prostate cancer.

Released: February 22, 2022

Expiration: February 21, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Maha Hussain, MD, FACP, FASCO

Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Maha Hussain, MD, FACP, FASCO, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Novartis, Pfizer and Tempus and funds for research support paid to her institution from Arvinas, AstraZeneca, Bayer, and Genentech.